MedTrace Logo

Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults

NCT00850668 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2013-05-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and side effects of a study product that contains recombinant modified peanut proteins (EMP-123) in healthy and peanut-allergic participants. This is a first in human study.

As of November 2009, this study is no longer recruiting healthy volunteers and will only be recruiting individuals with peanut allergies.

Conditions

  • Food Hypersensitivity
  • Hypersensitivity
  • Immediate Hypersensitivity
  • Peanut Hypersensitivity

Interventions

BIOLOGICAL

E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3

Up to 7 mL solution administered rectally

Sponsors & Collaborators

  • Consortium of Food Allergy Research

    collaborator OTHER

  • Allertein Therapeutics, LLC

    lead INDUSTRY

Principal Investigators

  • Robert A. Wood, MD · Johns Hopkins University

  • Scott Sicherer, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00850668 on ClinicalTrials.gov